neoantigen peptide vaccine Neoantigen - Neoantigendetection neoantigen vaccines The Dawn of Personalized Oncology: Understanding the Neoantigen Peptide Vaccine

Splicingneoantigen The landscape of cancer treatment is rapidly evolving, moving towards highly personalized and targeted therapiesComparing neoantigen cancer vaccines and immune .... At the forefront of this revolution is the neoantigen peptide vaccine, a groundbreaking approach that harnesses the patient's own immune system to combat cancer. Unlike traditional treatments that broadly target cancer cells, neoantigen peptide vaccines are designed to recognize and attack the unique molecular signatures of an individual's tumor, offering the potential for greater efficacy with fewer side effectsAbnormalpeptides, so-calledneoantigens, arise from DNA mutations in tumor cells and are targets for therapy using personalizedvaccines. CeGaT's CancerNeo® ....

At its core, a neoantigen peptide vaccine is a peptide-based cancer vaccine constructed from neoantigens. These neoantigens are abnormal peptides that arise from DNA mutations within tumor cells. These mutations lead to the production of altered proteins, and fragments of these altered proteins, known as neoantigens, are presented on the surface of cancer cells. Because these neoantigens are unique to the tumor and not found on healthy cells, they serve as ideal targets for a neoantigen vaccine. The development of neoantigen vaccines is a complex process that involves sequencing a patient's tumor to identify these specific mutations and then synthesizing peptides that precisely match these neoantigens作者：AC Wu·2025—Neoantigen-targetedvaccinesaim to activate specific T-cell responses by targeting mutations unique to an individual patient's tumor. Recent clinical trials of ....

The mechanism behind a neoantigen peptide vaccine is to stimulate a patient's immune system, specifically T-cells, to recognize and eliminate cancer cells expressing these unique neoantigens2025年4月2日—Mechanistically,peptide vaccinesare designed to induce humoral and cell-mediated anti-tumor immune responses. Vaccines may consist of .... This is achieved by administering synthesized peptides that are based on the identified neoantigens. When these peptides are introduced into the body, they are recognized by immune cells as foreign, triggering an immune response. This response then trains the immune system to identify and attack any cancer cells that present these specific neoantigens. Research is exploring various platforms for neoantigen vaccines, including synthetic long peptide vaccines, which extend short peptides to potentially enhance their effectiveness and overcome immune limitations.A neoantigen vaccine generates antitumour immunity in ...

The promise of neoantigen peptide vaccines is evident in numerous ongoing clinical trials and early-stage research.The development of neoantigen-derived peptide vaccine ... Studies are investigating their application across a range of solid tumors, including melanoma, non-small cell lung cancer (NSCLC), glioblastoma multiforme (GBM), and colorectal cancer (CRC).作者：AC Wu·2025—Neoantigen-targetedvaccinesaim to activate specific T-cell responses by targeting mutations unique to an individual patient's tumor. Recent clinical trials of ... For instance, some trials are evaluating the safety and efficacy of a personalized neoantigen peptide-based vaccine in combination with other immunotherapies like pembrolizumab or tislelizumab, as well as chemotherapy, for patients with advanced solid tumors or specific conditions like NSCLC and smoldering multiple myeloma. Early results from some first-in-human studies of personalized neoantigen vaccinations have demonstrated promising efficacy in preventing recurrence and improving survival, with a manageable safety profile.作者：CM Nguyen·2025·被引用次数：9—Keywords: Cancer immunotherapy; Lewis lung carcinoma;Neoantigen; Synthetic longpeptide vaccine; mRNA-LNPs; mRNA-based vaccine. © 2025. The ...

The personalization aspect is key to the success of neoantigen peptide vaccines. Each neoantigen peptide vaccine is tailored to the individual patient's tumor, making it a truly precision medicine approach. This contrasts with broader vaccines that target common cancer markers. The identification of neoantigens relies on advanced genomic sequencing of tumor samples.作者：S Keshari·2024·被引用次数：11—Here, we compared mutantneoantigen(neoAg)peptide-basedvaccineswith ICT in preclinical models. NeoAgvaccinesinduce the most robust ... Once these targets are identified, peptide vaccines are designed to induce both humoral and cell-mediated anti-tumor immune responses.A multi-adjuvant personal neoantigen vaccine generates ... The field is also exploring neoantigen-based mRNA vaccines, which utilize messenger RNA (mRNA) technology to instruct cells to produce specific neoantigens, thereby generating a robust immune response.

While the potential is immense, challenges remain. Improving immunogenicity is an ongoing area of research, as is understanding the optimal combination strategies with other cancer therapies.Personalized neoantigen vaccination with synthetic long ... Researchers are also investigating the role of neoantigen load in predicting treatment response and developing comprehensive neoantigen databases to accelerate the identification and targeting of these crucial biomarkers. The ultimate goal is to develop neoantigen vaccines that can offer more effective treatment with fewer adverse events, fundamentally changing the paradigm of cancer therapy and offering new hope for patients with aggressive cancers. The development of neoantigen-derived peptide vaccines represents a significant stride towards this future.